Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 with FOLFOX/Cetuximab vs FOLFOXIRI/Bevacizumab in Left-sided mCRC
NCT07070713Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab and tuvonralimab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07070713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070713.